U.S. markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
66.54+0.52 (+0.79%)
At close: 4:00PM EST

66.60 +0.04 (0.06%)
After hours: 7:47PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close66.02
Bid66.10 x 1300
Ask66.70 x 2900
Day's Range65.54 - 66.86
52 Week Range45.76 - 68.34
Avg. Volume10,565,496
Market Cap150.364B
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateFeb 04, 2021
Forward Dividend & Yield1.96 (3.03%)
Ex-Dividend DateDec 31, 2020
1y Target Est74.76
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-13% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know

    Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know

    Bristol-Myers Squibb (BMY) closed the most recent trading day at $66.54, moving +0.79% from the previous trading session.

  • Is Bristol-Myers Squibb (BMY) Stock a Buy For 2021?
    Insider Monkey

    Is Bristol-Myers Squibb (BMY) Stock a Buy For 2021?

    Wedgewood Partners recently released its Q4 2020 Investor Letter, a copy of which you can download here. The Fund returned 12.2% for the fourth quarter of 2020. Meanwhile, the benchmark S&P 500 Index and the Russell 1000 Growth Index gained 12.2% and 11.4%, respectively. You should check out Wedgewood Partners’ top 5 stock picks for […]

  • Benzinga

    Bristol-Myers Squibb's Debt Overview

    Over the past three months, shares of Bristol-Myers Squibb (NYSE: BMY) moved higher by 8.86%. Before having a look at the importance of debt, let us look at how much debt Bristol-Myers Squibb has.Bristol-Myers Squibb's Debt According to the Bristol-Myers Squibb's most recent financial statement as reported on November 5, 2020, total debt is at $44.95 billion, with $41.36 billion in long-term debt and $3.58 billion in current debt. Adjusting for $19.43 billion in cash-equivalents, the company has a net debt of $25.51 billion.Let's define some of the terms we used in the paragraph above. Current debt is the portion of a company's debt which is due within 1 year, while long-term debt is the portion due in more than 1 year. Cash equivalents include cash and any liquid securities with maturity periods of 90 days or less. Total debt equals current debt plus long-term debt minus cash equivalents.To understand the degree of financial leverage a company has, investors look at the debt ratio. Considering Bristol-Myers Squibb's $125.54 billion in total assets, the debt-ratio is at 0.36. As a rule of thumb, a debt-ratio more than one indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can also imply that the company might be putting itself at risk for default, if interest rates were to increase. However, debt-ratios vary widely across different industries. A debt ratio of 25% might be higher for one industry and average for another.Importance Of Debt Besides equity, debt is an important factor in the capital structure of a company, and contributes to its growth. Due to its lower financing cost compared to equity, it becomes an attractive option for executives trying to raise capital.However, due to interest-payment obligations, cash-flow of a company can be impacted. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.Looking for stocks with low debt-to-equity ratios? Check out Benzinga Pro, a market research platform which provides investors with near-instantaneous access to dozens of stock metrics - including debt-to-equity ratio. Click here to learn more.See more from Benzinga * Click here for options trades from Benzinga * AutoNation's Debt Overview * Recap: JPMorgan Chase Q4 Earnings(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.